Premium
p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas
Author(s) -
Benhattar Jean,
Cerottini JeanPhilippe,
Saraga Emilia,
Metthez Geneviève,
Givel JeanClaude
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960621)69:3<190::aid-ijc7>3.0.co;2-v
Subject(s) - colorectal cancer , cancer research , chemotherapy , metastasis , tumor suppressor gene , oncology , medicine , fluorouracil , regimen , chemotherapy regimen , biology , cancer , carcinogenesis
Although intrahepatic infusion therapy with 5‐flourouracil for unresectable colorectal liver metastases may lead to improved overall survival for some patients, it is not clear why a response is not observed in others. Gene alterations in oncogenes or tumor‐suppressor genes are critical events in tumor formation, and some of them could play a role in the process of drug resistance. The tumor‐suppressor gene p53 , which is known to trigger cell arrest or apoptosis in response to DNA damage, is found to be mutated in a wide range of human tumors. The aim of this work is to establish whether a relationship is found between p53 mutations and survival in patients undergoing adjuvant chemotheraphy for advanced Dukes' D colorectal cancers. Seventeen tumors from patients treated with 5‐fluorouracil regimen via intrahepatic infusion for unresectable colorectal hepatic metastasis were considered. p53 mutations from tumor DNA were detected, after amplification by PCR of exons 5 to 8, by non‐radioactive single‐strand conformation polymorphism and direct DNA sequencing. Patients with mutated p53 colorectal tumors had short survival, whereas prolonged survival was associated with the presence of wild‐type p53 ( p = 0.019). Our data suggest that mutated p53 colorectal tumors had a weak response, or even no response, to chemotherapeutic treatment. Routine assessment of p53 status would be helpful in selecting patients with only wild‐type p53 gene who have a predictably better response to chemotherapy. © 1996 Wiley‐Liss, Inc.